Advertisement

Topics

German Community of Gynecological Oncology (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence

04:00 EST 8 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
2017 Guidelines of the AGO Breast Committee acknowledges Agendia’s MammaPrint test with highest medical evidence level 1A for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer ...

Other Sources for this Article

Media :
Instinctif Partners
Léon Melens (Netherlands media)
+31 6 538 16 427
or
Daniel Gooch (EU media)
+44 20 7866 7905
or
Samantha Schmidt (German media)
+49 30 240 8304-14
agendia@instinctif.com

NEXT ARTICLE

More From BioPortfolio on "German Community of Gynecological Oncology (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...